A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2017
At a glance
- Drugs Cariprazine (Primary)
- Indications Bipolar I disorders
- Focus Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 24 Jun 2016 Planned End Date changed from 1 Jun 2018 to 1 Jul 2018.
- 24 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Feb 2016 New trial record